News

Lipid Test Flags Renal Impairment Risk in Lupus


 

A simple serum lipid test may identify patients with systemic lupus erythematosus who are at an increased risk for renal dysfunction, according to investigators.

Data collected on 1,060 patients with SLE who were registered at the University of Toronto Lupus Databank were analyzed by Annaliese Tisseveras and her colleagues.

They found that an elevated serum total cholesterol level in the first sample obtained from patients and recorded in the databank was significantly associated with subsequent renal deterioration and death associated with kidney dysfunction (Arthritis Rheum. 2006;54:2211-9).

“Independent of any association with proteinuria or steroid therapy, an elevated total cholesterol level portends a worse renal outcome,” reported Ms. Tisseveras and her colleagues at Toronto Western Hospital. More research is needed, they noted, but “the predictive value of an elevated cholesterol level on renal function … cannot be discounted.”

The patients, who were mostly women, had a mean age of 36 years and a mean duration of SLE of 4 years when the first total cholesterol measurement was recorded. The first measurement ranged from 1.6 to 17.1 mmol/L, with a mean of 5.3 mmol/L (205 mg/dL).

During an average follow-up of almost 9 years, 9% of patients experienced renal deterioration, 4% developed end-stage renal disease (ESRD), and 15% died (30% of the deaths were associated with renal dysfunction). The investigators stratified patients into two groups: those with normal total cholesterol levels and those with elevated levels. They then looked at Kaplan-Meier survival estimates for each of the three outcomes—renal deterioration, ESRD, and death. The estimates for each of the outcomes, they found, were significantly different between the two groups, with worse outcomes in the group with elevated total cholesterol levels.

In multivariate analyses that included other variables, baseline proteinuria and serum creatinine level were predictive of both ESRD and renal deterioration. Total cholesterol level did not retain its significance with regard to ESRD, however, which may be due to the low number of patients with ESRD.

Total cholesterol level did, however, correlate again with death, and significantly with renal death—a finding that is “strongly supportive of a pathogenic role for hypercholesterolemia in SLE renal disease,” the investigators reported.

Recommended Reading

Managing a Drug's Hepatic Risks: The Bosentan Example
MDedge Rheumatology
BP Control Key to Lupus Nephritis Care in Pregnancy
MDedge Rheumatology
Refractory Ocular Sarcoidosis Responded to Infliximab
MDedge Rheumatology
Walking Test Not a Good Indicator of Lung Function in Interstitial Disease
MDedge Rheumatology
Sclerosis Sine Scleroderma May Not Be All That Rare
MDedge Rheumatology
Flu Vaccine Found Less Effective in SLE Patients
MDedge Rheumatology
Lupus Nephritis Responds to Low-Dose Cyclophosphamide
MDedge Rheumatology
In-Depth Health Care Info Available
MDedge Rheumatology
Lupus Features Vary Dramatically by ANA Status
MDedge Rheumatology
Bosentan Aids Heart Function in Systemic Sclerosis
MDedge Rheumatology